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Mitral Regurgitation?*
Michael Ragosta, MDM itral regurgitation (MR) can be classi-ﬁed as either degenerative or functional.Degenerative MR is due to disease, defor-
mity, or damage of the mitral valve or its supporting
apparatus. Functional MR is caused by improper
coaptation of normal leaﬂets and apparatus and is
due primarily to abnormalities of the left ventricle.
Ischemic MR is a subset of functional MR (papillary
muscle rupture, a mechanical complication of acute
myocardial infarction [MI], is a rare exception). MR
is commonly observed in patients with heart failure,
recent or remote MI, and ischemic cardiomyopathy.
The prevalence ranges from 10% to 70% (1). This
broad range is due to differences in the method
used to deﬁne MR, the population studied, and the
time frame after MI that analysis was performed.
Although the exact prevalence is unknown, some
degree of MR is clearly common. Most patients have
mild regurgitation. Moderate to severe regurgitation
is reported in 10% to 20% of patients with ischemic
heart disease (2–5). MR is also seen after non–
ST-segment elevation myocardial infarction with
1 report observing MR in 40% of non–ST-segment
elevation myocardial infarction patients with <5%
exhibiting severe MR (6).
The presence of MR in patients with ischemic
heart disease is a powerful predictor of adverse
events (2–4,7). An analysis of 303 patients several
weeks after transmural infarction found some degree
of MR in 64% of patients (2). Patients with MR had
a greater mortality than those without regurgitation
and this was independent of other variables and was*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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tricular dysfunction. Furthermore, the degree of MR
was related to mortality; even patients with mild to
moderate regurgitation experienced worse outcomes
than did patients without regurgitation. Similar ﬁnd-
ings were reported in a large cohort of patients stud-
ied within 30 days of MI (3). Moderate or severe MR
was associated with a large increase in risk of heart
failure or death and mild degrees of regurgitation
were associated with a greater likelihood of death.
Contrary to previous beliefs, ischemic MR is not
due to ischemia and dysfunction of the papillary
muscle. Instead, regurgitation is due to heteroge-
neous and complex mechanisms that ultimately pre-
vent closure of the leaﬂets, thereby creating the
characteristic central jet of functional MR. These
complex mechanisms have been described (5,8). To
summarize, ischemic MR may be due to: 1) alter-
ations in left ventricular geometry; 2) distortion and
enlargement of the mitral annulus; and 3) dyssyn-
chrony of ventricular contraction that can interfere
with normal valve closure. The most important of
these are the alterations of left ventricular geometry
that occur with infarction.
Closure of the mitral valve depends on 2 opposing
forces. A tethering force from the papillary muscles
and chordae pulls the leaﬂets away from the annulus
during systole. A closing force occurs during systole
and pushes the leaﬂets closed. An imbalance in these
forces prevents proper closure. Infarction and ven-
tricular remodeling distort the papillary muscles
and surrounding myocardium, thereby increasing the
tethering forces.
Tethering is the most important mechanism for
ischemic MR, and additional mechanisms contribute.
Severe left ventricular dysfunction reduces the force
of systolic contraction and reduces the closing force.
Ventricular enlargement stretches and enlarges the
mitral annulus preventing proper coaptation of the
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duced closing force and disturbed coordination of
papillary muscle contraction affecting its tethering
function. These mechanisms are important to un-
derstand when contemplating therapies to reduce
MR in patients with ischemic cardiomyopathy.SEE PAGE 355In this issue of JACC: Cardiovascular Interventions,
Zeng et al. (9) offer a novel method to treat ischemic
MR. An injection of polyvinyl alcohol hydrogel poly-
mer into infarcted myocardium adjacent to the papil-
lary muscles would, in theory, stabilize the zone
and prevent the geometric changes that occur from
remodeling, thereby preventing tethering and re-
ducing MR. Using an experimental model of infarction
in sheep, the investigators injected the infarct zone
with the polymer; a control group was injected with
saline. Eight weeks later, the sheep injected with
polymer had less MR, improved left ventricular func-
tion, and improved indices of remodeling and mitral
valve geometry. These parameters did not change in
control animals.
Now that we understand its prevalence, prognostic
implications, and mechanisms, what do we do about
ischemic MR? Despite its association with worse
prognosis, it is entirely unclear whether reducing
the degree of MRwill change prognosis as there is little
to no data to support this concept. To date, treatment
has been mostly medical therapy or surgical
repair with mitral annuloplasty at the time of coronary
revascularization surgery (10). Percutaneous ap-
proaches have been proposed. The Monarc device
(American Medical Systems, Minnetonka, Minnesota)
is a transcatheter method relying upon the proximity
of the coronary sinus to the mitral annulus in an effort
to achieve a percutaneous annuloplasty. This device,
however, was associated with coronary artery
compression and MI and only modestly affected the
degree of MR (11). The mitral clip (MitraClip, Abbott
Vascular, Santa Clara, California), a percutaneous
edge-to edge repair, shows more promise. In terms of
mechanism, the mitral clip might prove useful in
functional MR by targeting the distorted annulus
associated with this condition. In fact, the mitral cliphas been shown to reduce mitral annular dimensions
in functional MR, and this is associated with clinical
improvement (12). Although there are no randomized
data to support its use in the functional MR subset, it is
widely used for this indication in Europe. In fact, 72%
of patients treated with the mitral clip in a European
registry had functional MR (13). Procedural success,
reduction of MR, and 1-year mortality were similar for
patients with functional and degenerative MR. Inter-
estingly, the 1-year rehospitalization rate for heart
failure was higher for patients with functional versus
degenerative MR, suggesting that the underlying left
ventricular dysfunction might be a more important
determinant of outcome than the degree of MR. The
COAPT (Cardiovascular Outcomes Assessment of the
MitraClip Percutaneous Therapy for Heart Failure Pa-
tients with Functional Mitral Regurgitation) trial
(NCT01626079) is designed to speciﬁcally address the
role of the mitral clip in this population.
By stabilizing the infarction zone and limiting
remodeling, the method proposed in this issue by
Zeng et al. (9) is particularly attractive as it addresses
the most important mechanism of ischemic MR:
distortion of ventricular geometry and abnormal
tethering. However, implementing this strategy in
humans and designing a clinical trial will prove
extremely challenging. The clinical device must be
percutaneous, and the operator would need to iden-
tify the precise location to inject the polymer, thus
requiring advanced imaging during the procedure.
Unanswered questions include the optimal volume
of polymer, the optimal location in the ventricle, and
the most effective time frame after MI. Additionally,
which patients are candidates for this therapy? It is
not clear whether efforts should focus only on those
with severe MR or on patients with lesser degrees
of MR. Remember though, as stated earlier, it is not
entirely clear that reducing MR will change prognosis
in patients with ischemic MR. Perhaps that question
should be answered ﬁrst.
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